MA42006A1 - Molécules hybrides - Google Patents

Molécules hybrides

Info

Publication number
MA42006A1
MA42006A1 MA42006A MA42006A MA42006A1 MA 42006 A1 MA42006 A1 MA 42006A1 MA 42006 A MA42006 A MA 42006A MA 42006 A MA42006 A MA 42006A MA 42006 A1 MA42006 A1 MA 42006A1
Authority
MA
Morocco
Prior art keywords
hybrid molecules
applications
pyochelin
inhibit
growth
Prior art date
Application number
MA42006A
Other languages
English (en)
Inventor
Christian Lange
Carsten Corvey
Heike Stump
Jochen Kruip
Bernhard Calandra
Astrid Rey
Michael Mourez
Laurent Fraisse
Christine Rothe
Andrea Allersdorfer
Alexander Wiedenmann
Marlon Hinner
Bradley Lunde
Kristian Jensen
Martin Hülsmeyer
Ingo Focken
Dorothea Rat
Thomas Stuedemann
Hans-Falk Rasser
Juergen Schaefer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA42006A1 publication Critical patent/MA42006A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne des molécules hybrides qui présentent une spécificité de liaison pour la pyoverdine de type i, ii et iii et la pyochéline et peuvent être utilisées dans diverses applications, y compris des applications diagnostiques et/ou thérapeutiques, par exemple, pour inhiber ou réduire la croissance de
MA42006A 2015-07-07 2016-07-06 Molécules hybrides MA42006A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306106.4A EP3115371A1 (fr) 2015-07-07 2015-07-07 Molécules de fusion
PCT/EP2016/065899 WO2017005763A1 (fr) 2015-07-07 2016-07-06 Molécules hybrides

Publications (1)

Publication Number Publication Date
MA42006A1 true MA42006A1 (fr) 2018-09-28

Family

ID=53719726

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42006A MA42006A1 (fr) 2015-07-07 2016-07-06 Molécules hybrides

Country Status (26)

Country Link
US (2) US10316071B2 (fr)
EP (2) EP3115371A1 (fr)
JP (1) JP2018524003A (fr)
KR (1) KR20180026755A (fr)
CN (1) CN107849106A (fr)
AR (1) AR105257A1 (fr)
AU (1) AU2016289839A1 (fr)
BR (1) BR112018000155A2 (fr)
CA (1) CA2991298A1 (fr)
CL (1) CL2018000015A1 (fr)
CO (1) CO2018001188A2 (fr)
CR (1) CR20180079A (fr)
DO (1) DOP2018000001A (fr)
EA (1) EA201890234A1 (fr)
EC (1) ECSP18008488A (fr)
HK (1) HK1249110A1 (fr)
IL (1) IL256694A (fr)
MA (1) MA42006A1 (fr)
MX (1) MX2018000206A (fr)
PE (1) PE20180490A1 (fr)
PH (1) PH12018500058A1 (fr)
TN (1) TN2017000547A1 (fr)
TW (1) TW201716435A (fr)
UY (1) UY36772A (fr)
WO (1) WO2017005763A1 (fr)
ZA (1) ZA201708754B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3259282A1 (fr) 2015-02-18 2017-12-27 Sanofi Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
EP3115371A1 (fr) 2015-07-07 2017-01-11 Sanofi Molécules de fusion
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CN111848734B (zh) * 2020-06-17 2022-04-05 自然资源部第三海洋研究所 一种具有荧光特性的铁载体pvd、制备方法及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (fr) 1998-03-31 1999-09-30 Hemosol Inc. Complexes d'amidon hydroxyethyles d'hemoglobine
JP3839667B2 (ja) 1998-06-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
US7056702B2 (en) 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US8420051B2 (en) * 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
JP2013529907A (ja) * 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
EP2920202B1 (fr) * 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Nouveaux polypeptides se liant specifiquement, et leur utilisation
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
EP3259282A1 (fr) 2015-02-18 2017-12-27 Sanofi Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
EP3298029A1 (fr) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Mutéines de la lipocaline 2 humaine avec affinité pour glypican-3 (gpc3)
EP3115371A1 (fr) * 2015-07-07 2017-01-11 Sanofi Molécules de fusion

Also Published As

Publication number Publication date
HK1249110A1 (zh) 2018-10-26
EP3115371A1 (fr) 2017-01-11
CN107849106A (zh) 2018-03-27
ECSP18008488A (es) 2018-04-30
TW201716435A (zh) 2017-05-16
BR112018000155A2 (pt) 2018-09-11
PH12018500058A1 (en) 2018-07-09
TN2017000547A1 (en) 2019-04-12
EA201890234A1 (ru) 2018-06-29
JP2018524003A (ja) 2018-08-30
DOP2018000001A (es) 2018-05-15
EP3319986A1 (fr) 2018-05-16
US20190382455A1 (en) 2019-12-19
UY36772A (es) 2017-01-31
US10947284B2 (en) 2021-03-16
US10316071B2 (en) 2019-06-11
CL2018000015A1 (es) 2018-07-13
US20170029477A1 (en) 2017-02-02
AR105257A1 (es) 2017-09-20
MX2018000206A (es) 2018-02-26
IL256694A (en) 2018-03-29
ZA201708754B (en) 2018-11-28
CA2991298A1 (fr) 2017-01-12
PE20180490A1 (es) 2018-03-07
AU2016289839A1 (en) 2018-03-01
CO2018001188A2 (es) 2018-05-10
CR20180079A (es) 2018-04-24
KR20180026755A (ko) 2018-03-13
WO2017005763A1 (fr) 2017-01-12

Similar Documents

Publication Publication Date Title
MA41013A (fr) Compositions comprenant des souches bactériennes
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
MA42560A (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
EA201990043A1 (ru) Антибактериальные соединения
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA44322A (fr) Compositions comprenant des souches bactériennes
MX2018000470A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22).
MA42471A (fr) Compositions comprenant des souches bactériennes
EA201890201A1 (ru) Антибактериальные соединения
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
CL2018000092A1 (es) Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.
EA201791174A1 (ru) Антимикотическое соединение
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
PH12018500058A1 (en) Fusion molecules
GB2564990A (en) Topical compositions for neuropathic pain
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
FR3038605B1 (fr) Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
MA39336A1 (fr) Molécules d'anticorps anti-lag-3 et leurs utilisations